Literature DB >> 32171048

Revisit of test-then-pool methods and some practical considerations.

Wen Li1, Frank Liu1, Duane Snavely1.   

Abstract

Test-then-pool is a simple statistical method that borrows historical information to improve efficiency of the drug development process. The original test-then-pool method examines the difference between the historical and current information and then pools the information if there is no significant difference. One drawback of this method is that a nonsignificant difference may not always imply consistency between the historical and current information. As a result, the original test-then-pool method is more likely to incorrectly borrow information from the historical control when the current trial has a small sample size. Statistically, it is more natural to use an equivalence test for examining the consistency. This manuscript develops an equivalence-based test-then-pool method for a continuous endpoint, explains the relationship between the two test-then-pool methods, explores the choice of an equivalence margin through the overlap probability, and proposes an adjustment to the nominal testing level for controlling type I error under the true consistency scenario. Furthermore, the analytical forms of the type I error and power for the two test-then-pool methods are derived, and practical considerations for using them are presented.
© 2020 John Wiley & Sons Ltd.

Keywords:  equivalence test; historical data borrowing; power; test-then-pool; type I error

Mesh:

Year:  2020        PMID: 32171048     DOI: 10.1002/pst.2009

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  Summarising salient information on historical controls: A structured assessment of validity and comparability across studies.

Authors:  Anthony Hatswell; Nick Freemantle; Gianluca Baio; Emmanuel Lesaffre; Joost van Rosmalen
Journal:  Clin Trials       Date:  2020-09-21       Impact factor: 2.486

2.  Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.

Authors:  Elias Laurin Meyer; Peter Mesenbrink; Cornelia Dunger-Baldauf; Ekkehard Glimm; Yuhan Li; Franz König
Journal:  Pharm Stat       Date:  2022-01-31       Impact factor: 1.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.